Biogen stock rises on Q1 results, Alzheimer's drug sales

Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi.

Yahoo Finance's Anjalee Khemlani breaks down the details of the report.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Angel Smith